Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Amgen Inc.
IndexS&P 500 P/E17.39 EPS (ttm)6.64 Insider Own0.10% Shs Outstand756.49M Perf Week1.18%
Market Cap87.34B Forward P/E13.25 EPS next Y8.72 Insider Trans33.54% Shs Float755.64M Perf Month-8.78%
Income5.08B PEG2.28 EPS next Q1.93 Inst Own82.50% Short Float1.40% Perf Quarter-2.51%
Sales18.68B P/S4.68 EPS this Y20.30% Inst Trans0.09% Short Ratio2.80 Perf Half Y1.97%
Book/sh29.23 P/B3.95 EPS next Y6.94% ROA8.90% Target Price132.05 Perf Year9.40%
Cash/sh25.65 P/C4.50 EPS next 5Y7.63% ROE24.20% 52W Range92.88 - 128.96 Perf YTD1.73%
Dividend2.44 P/FCF20.88 EPS past 5Y12.00% ROI10.50% 52W High-10.47% Beta0.61
Dividend %2.11% Quick Ratio3.10 Sales past 5Y4.50% Gross Margin82.10% 52W Low24.32% ATR3.55
Employees20000 Current Ratio3.40 Sales Q/Q13.30% Oper. Margin32.60% RSI (14)40.97 Volatility3.02% 3.13%
OptionableYes Debt/Eq1.45 EPS Q/Q31.70% Profit Margin27.20% Rel Volume0.86 Prev Close115.54
ShortableYes LT Debt/Eq1.34 EarningsApr 22 AMC Payout27.90% Avg Volume3.78M Price115.46
Recom2.30 SMA20-3.79% SMA50-5.31% SMA2001.29% Volume3,231,345 Change-0.07%
21-Mar-14Reiterated Barclays Equal Weight $115 → $130
31-Jan-14Reiterated Argus Buy $130 → $135
20-Nov-13Reiterated Deutsche Bank Buy $138 → $142
29-Aug-13Reiterated UBS Buy $121 → $124
27-Aug-13Reiterated Barclays Overweight $105 → $115
31-Jul-13Reiterated Oppenheimer Perform $100 → $109
24-Apr-13Reiterated Deutsche Bank Buy $108 → $115
15-Apr-13Reiterated Barclays Equal Weight $90 → $105
08-Apr-13Reiterated RBC Capital Mkts Outperform $95 → $105
25-Jan-13Upgrade Argus Hold → Buy $96
24-Jan-13Reiterated UBS Buy $96 → $98
12-Sep-12Downgrade Robert W. Baird Outperform → Neutral $84
10-Sep-12Upgrade UBS Neutral → Buy $80 → $96
02-Aug-12Downgrade Argus Buy → Hold
15-Mar-12Resumed Stifel Nicolaus Hold
09-Feb-12Downgrade Oppenheimer Outperform → Perform
09-Sep-11Downgrade Standpoint Research Buy → Hold
10-May-11Reiterated MP Advisors Outperform $63 → $65
25-Apr-11Reiterated Stifel Nicolaus Buy $70 → $68
21-Apr-11Reiterated Oppenheimer Outperform $66 → $63
17-Apr-14 05:03PM  FDA Grants Fast Track Status To Amgen Heart Failure Drug at Forbes
04:10PM  Emergent BioSolutions Gains on Trial News Zacks
04:05PM  Amgen Announces Webcast of 2014 First Quarter Financial Results PR Newswire
02:34PM  A Real Dividend Growth Machine: Q1 2014 Review at Seeking Alpha
01:22PM  [video] Kudlow: Two economic cycles at CNBC
09:32AM  Earnings Primer: What's on Deck for Amgen Inc. and Biogen Idec Inc. at Motley Fool
16-Apr-14 03:10PM  Dynavax Starts Phase III Study on Heplisav-B Zacks
05:00AM  'Fast Money' Recap: Impressed by Yahoo! at TheStreet
15-Apr-14 04:23PM  Nasdaq rides biggest trading rollercoaster in five years at CNBC
04:20PM  Encouraging Results from Lexicon Candidate Zacks
02:03PM  Capitulation or correction? Nasdaq nears 10% drop at CNBC
01:19PM  Another Earnings Beat from J&J, View Up Zacks
12:40PM  [video] Love biotech on correction: Trader at CNBC
12:37PM  [video] Top biotech analyst forecasts bottom at CNBC
06:49AM  Ambit Biosciences Slumps: AMBI Falls 13.0% in Session Zacks
05:00AM  'Fast Money' Recap: Long on Financials at TheStreet
14-Apr-14 06:14PM  Amgen's Conundrum at Motley Fool
03:30PM  Positive Results on Intercept Pharma's OCA Zacks
10:30AM  Gilead Bucks Biotech Trend Thanks to Sovaldi News Zacks
10:05AM  Momentum Investing: When Leaders Become Laggards at Barrons.com
07:43AM  [video] Pro picks Gannett, Amgen & more at CNBC
12-Apr-14 12:01AM  [$$] The Highfliers Are Still Too High at Barrons.com
11-Apr-14 02:32PM  Are Celgene and Amgen Undervalued By the Market? at Motley Fool
08:42AM  [video] Here's what's pushing biotech lower: Expert at CNBC
08:32AM  3 Biotech Companies That Look To Be Good Buys After A Pullback at Seeking Alpha
12:06AM  This is the make-or-break level for biotech Talking Numbers
10-Apr-14 03:39PM  Gilead Announces Encouraging Sovaldi Data Zacks
03:37PM  Biotech: Like Lambs to the Slaughter at Barrons.com
03:03PM  'Very Volatile' Biotech, in Chart Form at The Wall Street Journal
01:09PM  Oh Biotech, You Are a Cruel Bitch at TheStreet
10:02AM  [video] Celgene CEO: Intellectual property is lifeblood of innovation at CNBC
08:22AM  3 Top-Ranked Biotech Stocks on the Rebound Zacks
07:40AM  Moodys Levesque Says Heath Care Ratings at Risk (Audio) at Bloomberg
09-Apr-14 05:30PM  Oncolytics Reports Additional Data on Reolysin Zacks
10:50AM  Positive Trial Data Lifts Alkermes Zacks
08-Apr-14 02:38PM  Amgen: Management's History Of Shareholder Friendliness at Seeking Alpha
11:10AM  Halozyme Falls on Phase II Study Halt Zacks
08:47AM  AMGEN INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
06:31AM  Zacks Rank #1 Additions for Tuesday Zacks
07-Apr-14 05:43PM  [video] Biotech breakdown? at CNBC
12:10PM  Amgen's Oncology Candidate Disappoints Zacks
11:23AM  Pfizer Breast-Cancer Drug Scores, But Street Cautious at Investor's Business Daily
04-Apr-14 10:28PM  The Biggest Dividends Arent Necessarily the Best at New York Times
03:45PM  Glaxo and Amgen Terminate Agreement Zacks
12:18PM  Midday movers: GrubHub, Amgen, Disney & more at CNBC
11:33AM  Amgen melanoma drug fails to improve overall survival rates Reuters
10:02AM  Amgen melanoma drug shrinks tumors but fails secondary study goal Reuters
09:30AM  [$$] Amgen's Melanoma Treatment Study Disappoints at The Wall Street Journal
09:00AM  Amgen Provides Update On Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma PR Newswire
08:01AM  Zacks Rank #1 Additions for Friday Zacks
03-Apr-14 08:43PM  Amgen, Inc. Pays GlaxoSmithKline plc (ADR) to Go Away at Motley Fool
02:31PM  Does Amgen Have the Next Lipitor on Its Hands? at Motley Fool
11:52AM  AMGN May 23rd Options Begin Trading at TheStreet
11:12AM  Amgen, GSK End Marketing Partnership for Osteoporosis Drug at Fox Business
10:50AM  Amgen Faces Cool Reception Over GSK Pact Termination 24/7 Wall St.
09:58AM  Amgen ends marketing agreement with GSK for osteoporosis drug Reuters
09:20AM  AMGEN INC Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online
02-Apr-14 03:37PM  Biotech Giants Now Priced Like Old World Drug Stocks at 24/7 Wall St.
02:03PM  Gilead Sciences: What If Sovaldi Sales Peak Quickly, Fall Fast? at Barrons.com
11:16AM  Entia: An Iron-Clad Opportunity in a Billion Dollar Market Accesswire
01-Apr-14 04:09PM  Stocks rise as US manufacturing recovers AP
02:31PM  Can This Drive Growth for Amarin Corporation plc? at Motley Fool
01:03PM  3 Stocks Driving The Drugs Industry Higher at TheStreet
12:54PM  Health care stocks are outperforming; consider these picks from analyst Les Funtleyder Breakout
11:52AM  Stocks rise as US manufacturing recovers AP
05:57AM  [$$] Three Reasons to Be Cautious on Pfizer at Barrons.com
31-Mar-14 03:20PM  Todays Top Biotech Stories: Curis, Amgen, and Novartis at Motley Fool
03:03PM  Finding a Niche for Celgene's Otezla at Motley Fool
03:00PM  [video] 3 to Watch: AMGN, TEVA & GM at CNBC
02:51PM  [video] Injectable cholesterol drugs to face challenges at CNBC
01:59PM  Amgen Stock Gets Bump Up On Cholesterol Drug Data at Investor's Business Daily
01:19PM  [video] New class of cholesterol drugs at CNBC
12:18PM  Midday Movers: Amgen, Biogen, Priceline & More at CNBC
11:41AM  Amgen's Good News Bad News for Regeneron? at Barrons.com
10:31AM  Amgen: Allowing Dividend Growth Investors To Capitalize On The Biotech Sell-Off at Seeking Alpha
10:06AM  Stocks extend gains amid Fed Chair Yellen remarks; Dow spikes 150 at CNBC
09:23AM  Morning Movers: Biogen Jumps on FDA Approval; Big Lots Gains on Upgrade at Barrons.com
07:42AM  Amgen, McDermott International, Bank of America, Wells Fargo and McGraw Hill Financial highlighted as Zacks Bull and Bear of the Day Zacks
07:00AM  Amgen Drug Cuts Cholesterol Levels In Pivotal Studies at TheStreet
01:00AM  Bull of the Day: Amgen (AMGN) Zacks
30-Mar-14 08:00AM  Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins PR Newswire
29-Mar-14 05:10PM  Amgen Drug Slashes Bad Cholesterol Within Weeks of Treatment Bloomberg
05:10PM  Amgen Drug Slashes Bad Cholesterol Within Weeks of Treatment at Bloomberg
02:00PM  New Detailed Data from Three Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medicine Evolocumab Significantly Reduced LDL Cholesterol By 55-66 Percent Compared To Placebo In Patients With High Cholesterol PR Newswire
02:00PM  Amgen drug lowers cholesterol up to 66 pct in pivotal studies Reuters
28-Mar-14 05:50PM  Biotech: Past Performance Doesn't Predict the Future at Barrons.com
11:00AM  Aegerion Pharmaceuticals Viability Threatened As Regulatory, Legal And Market Forces Close In at Seeking Alpha
07:39AM  Cytokinetics announces opening to enrollment of COSMIC-HF expansion theflyonthewall.com
05:00AM  'Fast Money' Recap: Downward Pressure at TheStreet
27-Mar-14 05:36PM  [video] Biotech: Buy the dip? at CNBC
04:39PM  House approves bill to stop cut to Medicare docs AP
11:13AM  Amgen: Overlooked, Worth Buying, Morgan Stanley Says at Barrons.com
10:39AM  Amgen - On Course To Change The Future at Seeking Alpha
08:55AM  Morgan Stanley Starts Mixed Coverage on Top Biotech Stocks at 24/7 Wall St.
26-Mar-14 06:31PM  Is Idera's Sell-Off Premature? at Motley Fool
06:26PM  Merck, Glaxo end co-pay assistance for Obamacare plans Reuters
04:48PM  [$$] Biotech Stocks Break Down, a Bad Omen at Barrons.com
04:18PM  Amgen To Webcast Investor Meeting At Upcoming American College of Cardiology's 63rd Annual Scientific Session PR Newswire
04:10PM  [$$] Biotech Stocks Break Down, a Bad Omen at Barrons.com
08:16AM  The Zacks Analyst Blog Highlights: IShares NASDAQ Biotechnology ETF, Gilead, Alexion Pharmaceuticals, Amgen and Myriad Genetics Zacks
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Its principal products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company's principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate, a thrombopoietic compound; and Vectibix, a human monoclonal antibody. The company's products in phase 3 clinical trial comprise Evolocumab, a human monoclonal antibody used for the treatment for dyslipidemia; Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC, or IV melanoma; and Trebananib for the treatment of ovarian cancer. Its other product in development stage includes Ivabradine, an oral drug for chronic heart failure and stable angina in patients with elevated heart rates. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and pharmaceutical wholesale distributors. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc.; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
de Carbonnel FrancoisDirectorMar 06Option Exercise54.4410,000544,35025,364Mar 07 05:23 PM
de Carbonnel FrancoisDirectorMar 06Sale126.691,000126,69018,343Mar 07 05:23 PM
BALTIMORE DAVIDDirectorFeb 26Option Exercise62.555,000312,75031,879Feb 26 08:28 PM
HENDERSON REBECCA MDirectorFeb 13Option Exercise62.4120,0001,248,16025,549Feb 14 04:34 PM
HENDERSON REBECCA MDirectorFeb 13Sale123.5320,0002,470,6805,549Feb 14 04:34 PM
Bradway Robert AChairman, CEO and PresidentFeb 12Option Exercise62.5565,0004,065,750216,040Feb 14 04:19 PM
AMGEN INC10% OwnerDec 17Buy7.00272,1421,904,994541,399Dec 18 06:09 PM
Balachandran MadhavanEVP, OperationsSep 04Option Exercise58.4318,0001,051,74059,133Sep 05 07:33 PM
Balachandran MadhavanEVP, OperationsSep 04Sale112.7618,0002,029,76834,851Sep 05 07:33 PM
BALTIMORE DAVIDDirectorAug 28Sale109.664,582502,46227,789Aug 30 05:36 PM
Amgen Ventures LLC10% OwnerJun 05Buy15.0016,666249,990334,126Jun 05 04:01 PM
Dittrich Thomas J.W.VP, Finance & CAOMay 22Option Exercise54.626,130334,79122,863May 24 05:18 PM
Dittrich Thomas J.W.VP, Finance & CAOMay 22Sale104.786,130642,29616,733May 24 05:18 PM
Balachandran MadhavanEVP, OperationsMay 21Option Exercise50.446,000302,64046,956May 21 08:18 PM
Balachandran MadhavanEVP, OperationsMay 21Sale103.286,000619,68134,851May 21 08:18 PM
HENDERSON REBECCA MDirectorMay 17Option Exercise55.767,000390,31013,898May 20 07:15 PM
HENDERSON REBECCA MDirectorMay 17Sale105.728,421890,3005,477May 20 07:15 PM
Patton Cynthia MSVP & CCOMay 16Option Exercise54.583,544193,43718,986May 17 05:42 PM
Patton Cynthia MSVP & CCOMay 16Sale105.013,544372,14815,442May 17 05:42 PM
BIONDI FRANKDirectorMay 14Option Exercise56.5010,000564,95039,780May 16 05:38 PM
PELHAM JUDITH CDirectorMay 14Option Exercise55.4725,0001,386,65048,149May 16 05:42 PM
BIONDI FRANKDirectorMay 14Sale108.4310,0001,084,31829,780May 16 05:38 PM
PELHAM JUDITH CDirectorMay 14Sale108.2525,0002,706,16523,149May 16 05:42 PM
de Carbonnel FrancoisDirectorApr 30Option Exercise54.7410,000547,40021,930May 02 06:26 PM
MCNAMEE BRIAN MSVP, Human ResourcesApr 29Option Exercise50.4410,000504,40064,643Apr 30 05:21 PM
MCNAMEE BRIAN MSVP, Human ResourcesApr 29Sale107.0210,0001,070,19154,643Apr 30 05:21 PM
MCNAMEE BRIAN MSVP, Human ResourcesApr 26Option Exercise58.4310,000584,30066,077Apr 30 05:21 PM
MCNAMEE BRIAN MSVP, Human ResourcesApr 26Sale107.9910,0001,079,87256,077Apr 30 05:21 PM
MCNAMEE BRIAN MSVP, Human ResourcesApr 25Option Exercise54.698,662473,72565,973Apr 26 05:33 PM
MCNAMEE BRIAN MSVP, Human ResourcesApr 25Sale107.958,662935,02957,311Apr 26 05:33 PM
MCNAMEE BRIAN MSVP, Human ResourcesApr 24Sale105.956,924733,56558,311Apr 26 05:33 PM